Greater pressure on US imports in H2’22: Acerinox, from Overweight to Equalweight, T.P. 11,70 to 13,30 euros/share

AcerinoxTrading suspended in Acerinox shares on Aperam merger buzz

Morgan Stanley | The market is assuming normalised profits and not extrapolating the extraordinary profits in Q1 2022 due to macroeconomic uncertainties. For the time being, we remain neutral on the sector and are changing our order of preference.

Aperam has been the one which has most lagged behind out of all the steel stocks YTD. We believe the recent derating is exaggerated and its exposure to Europe clearly compensates that. In addition, in our view, the compression of the multiple seems exaggerated and its exposure to Europe more than offsets this. Whatsmore, reinvestment and accumulation of working capital point to a resilience in profits and EBITDA higher than the conversion of FCF as the cycle normalises.

In contrast Acerinox has already benefitted from its exposure to the US (upward revisions to profits) and the derating it has experienced is modest. Furthermore, we see greater pressure on imports in the US market in H2’22. This could negatively impact Acerinox’s margins. For that reason we are changing our tactical preference to Aperam (from EW to OW) over Acerinox (from OW to EW).

We lower our stance on Acerinox to Equalweight, Target Price from 11,70 to 13,30 euros/share.


About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.